Wegovy label consolidates four injection presentations plus tablets into one document

The prescribing information for Wegovy, dated June 18, 2026, now covers four separate injection presentations plus oral tablets in a single label under the same brand name ^[1][2]. The document lists a single-dose pen in five strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg per dose), a separate Wegovy HD single-dose pen delivering 7.2 mg, a single-dose prefilled syringe in five strengths, and the FlexTouch multi-dose pen that holds 9.6 mg total and delivers four 2.4 mg doses, alongside tablets in 1.5 mg, 4 mg, 9 mg and 25 mg strengths ^[1][2].

Each device comes with its own Instructions for Use, its own National Drug Code numbers, and its own storage window, according to the label ^[1][2]. The single-dose pen and single-dose syringe are good for 28 days once in use, the FlexTouch multi-dose pen is good for 56 days after first use, and the tablets are stored at USP controlled room temperature rather than tracked by an in-use countdown [Summary]. That means three different in-use rules now apply to products sold under one brand name, semaglutide, depending on which device a pharmacy dispenses [Summary].

The label also carries a new warning, added in June 2026, instructing that the FlexTouch pen must never be shared between patients, even if the needle is changed ^[1][2]. This addition sits in section 5.11 of the prescribing information, alongside other recent changes including revisions to the dosage and administration section made in August 2025, December 2025 and March 2026, and the removal of a suicidal behavior and ideation warning in either January or February 2026, depending on which version of the label is checked ^[1][2].

Why it matters for patients

People filling a Wegovy prescription may receive different devices at different times, whether because of pharmacy stock, insurance formulary rules, or a dose change during titration. Each device has different handling instructions and a different countdown clock once it is taken out of the refrigerator ^[1][2]. A patient who is used to the 28-day rule for a single-dose pen or syringe could unintentionally misapply it to a FlexTouch pen, which is rated for 56 days, or vice versa, potentially using a device past its intended window or discarding one that is still usable [Summary].

The tablets follow yet a third storage standard, USP controlled room temperature, with no injection-style in-use expiration to track [Summary]. This means the label now asks patients and caregivers to keep straight which format they have on hand and which rule applies to it, since all the products share the same brand name and the same active ingredient, semaglutide ^[1][2].

The new instruction against sharing the FlexTouch pen between patients, even with a fresh needle, reflects a general concern with multi-dose injection devices, though the label does not specify what prompted this addition in the June 2026 version ^[1][2]. Patients who use a multi-dose pen and live with others who also inject Wegovy or a similar product should be aware this instruction now appears explicitly on the label ^[1][2].

What happens next

The label notes a string of recent changes to dosage and administration sections in August 2025, December 2025 and March 2026, and to warnings sections in August, October 2025 and January or February 2026, suggesting the document continues to be revised as new device presentations and safety language are added ^[1][2]. No further scheduled changes are described in the sources beyond the June 2026 revision date itself ^[1][2].